DekaBank Deutsche Girozentrale bought a new position in shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 87,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,506,000.

A number of other large investors have also bought and sold shares of the stock. Gruss & Co. Inc. acquired a new stake in Valeant Pharmaceuticals International during the first quarter worth approximately $104,000. Financial Architects Inc increased its stake in Valeant Pharmaceuticals International by 18.6% in the first quarter. Financial Architects Inc now owns 9,550 shares of the specialty pharmaceutical company’s stock worth $105,000 after buying an additional 1,500 shares in the last quarter. Harbor Advisors LLC acquired a new stake in Valeant Pharmaceuticals International during the first quarter worth approximately $110,000. NEXT Financial Group Inc increased its stake in Valeant Pharmaceuticals International by 6.2% in the second quarter. NEXT Financial Group Inc now owns 10,303 shares of the specialty pharmaceutical company’s stock worth $178,000 after buying an additional 600 shares in the last quarter. Finally, WMS Partners LLC acquired a new stake in Valeant Pharmaceuticals International during the first quarter worth approximately $116,000. Institutional investors own 50.96% of the company’s stock.

Valeant Pharmaceuticals International, Inc. (NYSE VRX) opened at 14.14 on Tuesday. Valeant Pharmaceuticals International, Inc. has a 52-week low of $8.31 and a 52-week high of $32.74. The firm’s market capitalization is $4.93 billion. The stock’s 50 day moving average price is $16.09 and its 200 day moving average price is $13.39.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last announced its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, beating the consensus estimate of $0.97 by $0.08. The company had revenue of $2.23 billion during the quarter, compared to the consensus estimate of $2.23 billion. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The company’s revenue was down 7.7% on a year-over-year basis. During the same period last year, the firm earned ($0.88) earnings per share. Analysts expect that Valeant Pharmaceuticals International, Inc. will post $3.89 earnings per share for the current year.

WARNING: “DekaBank Deutsche Girozentrale Takes Position in Valeant Pharmaceuticals International, Inc. (VRX)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/08/22/dekabank-deutsche-girozentrale-takes-position-in-valeant-pharmaceuticals-international-inc-vrx.html.

A number of research firms have commented on VRX. Jefferies Group LLC set a $18.00 target price on Valeant Pharmaceuticals International and gave the company a “buy” rating in a research report on Saturday, May 6th. Piper Jaffray Companies set a $14.00 price objective on Valeant Pharmaceuticals International and gave the company a “sell” rating in a research note on Wednesday, August 9th. HC Wainwright set a $17.00 price objective on Valeant Pharmaceuticals International and gave the company a “hold” rating in a research note on Wednesday, August 9th. Canaccord Genuity set a $14.00 price objective on Valeant Pharmaceuticals International and gave the company a “hold” rating in a research note on Thursday, August 10th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Thursday, August 10th. Four investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Valeant Pharmaceuticals International presently has a consensus rating of “Hold” and a consensus target price of $17.81.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Want to see what other hedge funds are holding VRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.